{
    "nctId": "NCT00112749",
    "briefTitle": "Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer",
    "officialTitle": "Does Blocking Proinflammatory Cytokines Diminish Cancer-Related Fatigue?",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Fatigue",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 7,
    "primaryOutcomeMeasure": "Change in fatigue as measured by the fatigue symptom inventory (FSI)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women who report elevated fatigue following cancer diagnosis and treatment\n\nExclusion Criteria:\n\n* Women who have medical conditions that may affect the immune system or are associated with baseline fatigue syndrome, and/or who use medications that affect the immune system or fatigue.\n* Women with major affective disorders and those with sleep or pain disorders.\n* Presence of medical conditions that may but subject at undue risk for experimental procedures.\n* Chronic or recurring infections, symptoms of chronic heart failure, demyelinating disorders, and those taking immunosuppressive medications.\n* Neoplastic disease other than primary breast cancer\n* Compromised cardiovascular function\n* Insulin-dependent diabetes\n* Neurological disorder\n* Peripheral neuropathy\n* Pregnancy\n* Use of psychotropic medications within 2 weeks of screening\n* Abnormal screening laboratory findings (i.e., creatinine \\> 1.4mg%; anemia; abnormal thyroid hormone; hematuria; elevated liver function tests, low protein or albumin; fasting glucose \\>120mg%; elevated FTI or TSH; positive TB screening, HIV screening or hepatitis C).\n* Smokers",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}